Ovarian cancer is the deadliest gynecologic malignancy, with a 5-year survival rate of
approximately 47%, a number that has remained constant over the past two decades. Early …

Despite a good initial response to chemotherapy, the majority of patients with epithelial
ovarian cancer will eventually recur and die of their disease. The introduction of targeted …

Epigenetic aberrations, including DNA methylation, histone modifications, and micro-RNA
dysregulation, are now well established in the development and progression of ovarian …

Ovarian cancer therapy has remained fundamentally unchanged for 50 years, with surgery
and chemotherapy still the frontline treatments. Typically asymptomatic until advanced …

Ovarian cancer is the leading cause of death from gynaecological malignancies in the
Western world. Despite the evolution of surgical techniques and meticulously designed …

Ovarian cancer (OC) is one of the most common malignant tumors in women. OC is
associated with the activation of oncogenes, the inactivation of tumor suppressor genes, and …

Epithelial ovarian cancer has the highest mortality rate of all gynaecological malignancies.
Most women present with advanced disease and develop a recurrence after radical surgery …

Ovarian cancer is the most lethal of all gynecologic neoplasms. Early-stage malignancy is
frequently asymptomatic and difficult to detect and thus, by the time of diagnosis, most …

The involvement of epigenetic aberrations in the development and progression of tumors is
now well established. However, most studies have focused on the epigenetic inactivation of …

Epigenetic drugs have been shown to enhance gene expression and drug sensitivity in
ovarian cancer cell lines and animal models. Based on promising preclinical studies, DNA …